FI963049A0 - Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi - Google Patents

Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi

Info

Publication number
FI963049A0
FI963049A0 FI963049A FI963049A FI963049A0 FI 963049 A0 FI963049 A0 FI 963049A0 FI 963049 A FI963049 A FI 963049A FI 963049 A FI963049 A FI 963049A FI 963049 A0 FI963049 A0 FI 963049A0
Authority
FI
Finland
Prior art keywords
treatment
medicaments
manufacture
progesterone antagonists
bleeding due
Prior art date
Application number
FI963049A
Other languages
English (en)
Swedish (sv)
Other versions
FI963049A (fi
FI117850B (fi
Inventor
Kristof Chwalsz
Klaus Stoeckemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI963049A0 publication Critical patent/FI963049A0/fi
Publication of FI963049A publication Critical patent/FI963049A/fi
Application granted granted Critical
Publication of FI117850B publication Critical patent/FI117850B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI963049A 1995-02-02 1996-08-01 Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi FI117850B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP9500394 1995-02-02
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (3)

Publication Number Publication Date
FI963049A0 true FI963049A0 (fi) 1996-08-01
FI963049A FI963049A (fi) 1996-10-01
FI117850B FI117850B (fi) 2007-03-30

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963049A FI117850B (fi) 1995-02-02 1996-08-01 Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi

Country Status (20)

Country Link
US (1) US6451780B1 (fi)
EP (1) EP0806952B1 (fi)
JP (1) JPH10512889A (fi)
KR (1) KR100370908B1 (fi)
AT (1) ATE235907T1 (fi)
AU (1) AU714959B2 (fi)
CA (1) CA2186953C (fi)
DE (1) DE59510626D1 (fi)
DK (1) DK0806952T3 (fi)
ES (1) ES2196063T3 (fi)
FI (1) FI117850B (fi)
HU (1) HU226276B1 (fi)
MX (1) MX9603889A (fi)
NO (1) NO964155D0 (fi)
NZ (1) NZ287024A (fi)
PL (1) PL316533A1 (fi)
PT (1) PT806952E (fi)
SK (1) SK282570B6 (fi)
UA (1) UA37259C2 (fi)
WO (1) WO1996023503A1 (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
RS50283B (sr) 1999-08-31 2009-09-08 Bayer Schering Pharma Aktiengesellschaft, Mezoprogestini za lečenje i prevenciju benignih ginekoloških poremećaja
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7556150B2 (en) * 2004-06-07 2009-07-07 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of DUB
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
EP2148681B1 (en) * 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EA030444B1 (ru) 2012-05-31 2018-08-31 Репрос Терапьютикс Инк. Способ лечения прогестеронзависимого состояния
MX2015004821A (es) 2012-11-02 2015-08-14 Repros Therapeutics Inc Metodos y composiciones para tratar condiciones dependientes de la progesterona.
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3851444A1 (en) 2016-10-07 2021-07-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
NZ287024A (en) 2001-03-30
HU226276B1 (en) 2008-07-28
DE59510626D1 (de) 2003-05-08
UA37259C2 (uk) 2001-05-15
CA2186953A1 (en) 1996-08-08
AU2561195A (en) 1996-08-21
EP0806952A1 (de) 1997-11-19
HU9602668D0 (en) 1996-11-28
NO964155L (no) 1996-10-01
JPH10512889A (ja) 1998-12-08
PL316533A1 (en) 1997-01-20
US6451780B1 (en) 2002-09-17
ATE235907T1 (de) 2003-04-15
MX9603889A (es) 1997-04-30
KR100370908B1 (ko) 2003-04-10
HUT75930A (en) 1997-05-28
NO964155D0 (no) 1996-10-01
CA2186953C (en) 2009-11-10
AU714959B2 (en) 2000-01-13
SK282570B6 (sk) 2002-10-08
DK0806952T3 (da) 2003-06-16
WO1996023503A1 (de) 1996-08-08
FI963049A (fi) 1996-10-01
SK121996A3 (en) 1997-05-07
FI117850B (fi) 2007-03-30
PT806952E (pt) 2003-08-29
EP0806952B1 (de) 2003-04-02
KR970704451A (ko) 1997-09-06
ES2196063T3 (es) 2003-12-16

Similar Documents

Publication Publication Date Title
FI963049A0 (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
IT1201087B (it) Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO166367C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tieno-1,4-diazepiner.
NO880182D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1, 2-dihydro-3h-indazol-3h-indazol-3-on-derivater.
NO994850L (no) Farmakologiske midler
NO164656C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 1-(4-amionfenyl)-4-methyl-7,8-methylendioxy-3,4-dihydro-5h-2,3-benzodiazepin.
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
NO971869L (no) Konkurransedyktige progesteronantagonister for behovsorientert, kvinnelig fertillitetskontroll
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
PT1066304E (pt) Antagonistas macrolidos de lhrh
ES2111561T3 (es) Derivados de benzopirano antihipertensivos.
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
NO891025D0 (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktive sialosylglycerider.
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
AR026768A1 (es) Moleculas similares a antagonistas de receptores de interleukin-1 y usos de las mismas
NO862648L (no) Framgangsmÿte for framstilling av farmakologisk aktive 2-substituerte-3,4-dihydroksyfenyletylamino-derivater.
RU98112366A (ru) Препарат для лечения зудящих заболеваний
NO882279D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117850

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

MM Patent lapsed